[1] KESSLER R C, BERGLUND P, DEMLER O, et al. The epidemiology of major depressive disorder:Results from the National Comorbidity Survey Replication (NCS-R) . JAMA, 2003, 289(23):3095-3105.[2] KRISHNAN V, NESLER E J. The molecular neurobiology of depression . Nature, 2008, 455(7215):894-902.[3] KULKARNI S K,DHIR A. Current investigational drugs for major depression . Expert Opin Investig Drugs, 2009, 18(6):767-788.[4] WARNER-SCHMIDT J L, CHEN E Y, ZHANG X, et al. A role for p11 in the antidepressant action of brain-derived neurotrophic factor . Biol Psychiatry, 2010, 68(6):528-535.[5] TRIVEDI M H, RUSH A J, WISNIEWSKI S R, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D:Implications for clinical practice .Am J Psychiatry, 2006, 163(1):28-40.[6] MARICOURTD P, JAY T P, GONCALVES, et al. Ketamine′s antidepressant effect:Focus on ketamine mechanisms of action . Encephale, 2014, 40(1):48-55.[7] CADDY C, GIAROLI G, WHITE T P, et al. Ketamine as the prototype glutamatergic antidepressant:Pharmacodynamic actions, and a systematic review and meta-analysis of efficacy . Ther Adv Psychopharmacol, 2014, 4(2):75-99.[8] MITCHELL A J. Two-week delay in onset of action of antidepressants:New evidence . Br J Psychiatry, 2006, 188:105-110.[9] COLLINGRIDGE G L,BLISS T V. Memories of NMDA receptors and LTP . Trends Neurosci, 1995, 18(2):54-60.[10] SOFIA R D,HARAKAL J J. Evaluation of ketamine HCl for anti-depressant activity . Arch Int Pharmacodyn Ther, 1975, 214(1):68-74.[11] KRYSTAL J H, KARPER L P, SEIBYL J P, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses .Arch Gen Psychiatry, 1994, 51(3):199-214.[12] STRAYER R J,NELSON L S. Adverse events associated with ketamine for procedural sedation in adults . Am J Emerg Med, 2008, 26(9):985-1028.[13] GABLE R. Acute toxic effects of club drugs .J Psychoactive Drugs, 2004, 36(3):303-315.[14] LAIDLER K A J.The rise of club drugs in a heroin society:the case of Hong Kong .Subst Use Misuse, 2005, 40(9-10):1257-1278.[15] LANKENAU S E, SANDERS B, BLOOM J J, et al. First injection of ketamine among young injection drug users (IDUs) in three US cities .Drug Alcohol Depend, 2007, 87(2-3):183-193.[16] HAN Z L, ZHANG N H, ZHANG J B, et al. Contrast observation of sertraline, fluoxetine and paroxetine for the treatment of depression . Chin J Hosp Pharm(中国医院药学杂志), 2002, 22(5):293-295.[17] PARK S W, LEE J G, SEO M K, et al. Differential effects of antidepressant drugs on mTOR signalling in rat hippocampal neurons . Int J Neuropsychopharmacol, 2014, 17(11):1831-1846.[18] HU J P, ZHANG J L, SHENG Y X, et al. S (+) - ketamine hydrochloride in vivo pharmacokinetic study of rats . Chin Pharm J(中国药学杂志), 2009, 44(7):532-537.[19] ZARATE C J, SINGH J,HK M. Cellular plasticity cascades:Targets for the development of novel therapeutics for bipolar disorder . Biol Psychiatry, 2006, 59(11):1006-1020.[20] CLEMENS J, NIMMO W S, GRANT I S. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans . J Pharm Sci, 1982, 71(5):539-542.[21] MACHADO-VIEIRA R, SALVADORE G, DIAZGRANADOS N, et al. Ketamine and the next generation of antidepressants with a rapid onset of action . Pharmacol Ther, 2009, 123(2):143-150.[22] MESSER M, HALLER I V, LARSON P, et al. The use of a series of ketamine infusions in two patients with treatment-resistant depression . J Neuropsychiatry Clin Neurosci, 2010, 22(4):442-445.[23] LI N, LEE B, LIU R J, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.Science, 2010, 329(5994):959-964.[24] DUMAN R S, AGHAJANIAN G K.Synaptic dysfunction in depression:Potential therapeutic targets . Science, 2012, 338(6103):68-72.[25] HOLTMAAT A, SVOBODA K. Experience-dependent structural synaptic plasticity in the mammalian brain . Nat Rev Neurosci, 2009, 10(9):647-658.[26] KESSELS H W, MALINOW R. Synaptic AMPA receptor plasticity and behavior . Neuron, 2009, 61(3):340-350.[27] YOSHIHARA Y, DE R M, MULLER D. Dendritic spine formation and stabilization . Curr Opin Neurobiol, 2009, 19(2):146-153.[28] GEORGE M S, NAHAS Z, MOLLOY M, et al. A controlled trial of daily left prefrontal cortex TMS for treating depression . Biol Psychiatry, 2000, 48(10):962-970.[29] RADLEY J J, ROCHER A B, MILLER M, et al. Repeated stress induces dendritic spine loss in the rat medial prefrontal cortex . Cereb Cortex, 2006, 16(3):313-320.[30] RADLEY J J, ROCHER A B, RODRIGUEZ A, et al. Repeated stress alters dendritic spine morphology in the rat medial prefrontal cortex . J Comp Neurol, 2008, 507(1):1141-1150.[31] VILGIS V, CHEN J, SILK T J, et al. Frontoparietal function in young people with dysthymic disorder (DSM-5:Persistent depressive disorder) during spatial working memory . J Affect Disord, 2014, 160:34-42.[32] CHANDRAN A, IYO A H, JERNIGAN C S, et al. Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress . Prog Neuropsychopharmacol Biol Psychiatry, 2013, 40:240-244.[33] HAY N,SONENBERG N. Upstream and downstream of Mtor . Genes Dev, 2004, 18(16):1926-1945.[34] BEEVERS C S, LI F, LIU L, et al. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells . Int J Cancer, 2006, 119(4):757-764.[35] CORNU M, ALBERT V,HALL M N. mTOR in aging, metabolism, and cancer . Curr Opin Genet Dev, 2013, 23(1):53-62.[36] ZONCU R, EFEYAN A,SABATINI D M. mTOR:From growth signal integration to cancer, diabetes and ageing . Nat Rev Mol Cell Biol, 2011, 12(1):21-35.[37] CHEN H J, QU Y, MU D Z. The progress of study on the biological function of mTOR pathway .Chemistry of Life(生命的化学), 2010, 30(4):555-561.[38] MAENG S, ZARATE C A, DU J J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine:Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors . Biol Psychiatry, 2008, 63(4):349-352.[39] ZHAO J, BAO A M, QI X R, et al. Gene expression of GABA and glutamate pathway markers in the prefrontal cortex of non-suicidal elderly depressed patients . J Affect Disord, 2012, 138(3):494-502.[40] MOGHADDAM B, ADAMS B, VERMA A, et al. Activation of glutamatergic neurotransmission by ketamine:A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex . J Neurosci, 1997, 17(8):2921-2927.[41] HOEFFER C A, KLANN E. mTOR signaling:At the crossroads of plasticity, memory and disease . Trends Neurosci, 2010, 33(2):67-75.[42] LIVINGSTONE M, ATAS E, MELLER A, et al. Mechanisms governing the control of mRNA translation . Phys Biol, 2010, 7(2):021001.[43] PILC A, CHAKI S, NOWAK G, et al. Mood disorders:Regulation by metabotropic glutamate receptors . Biochem Pharmacol, 2008, 75(5):997-1006.[44] JOURDI H, HSU Y T, ZHOU M, et al. Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation . J Neurosci, 2009, 29(27):8688-8697.[45] TAKEI N, INAMURA N, KAWAMURA M, et al. Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites . J Neurosci, 2004, 24(44):9760-9769.[46] SLIPCZUK L, BEKINSCHTEIN P, KATCHE C, et al. BDNF activates mTOR to regulate GluR1 expression required for memory formation . PLoS One, 2009, 4(6):6007.[47] SHIN I J, SON S U, PARK H, et al. Preclinical evidence of rapid-onset antidepressant-like effect in Radix Polygalae extract . PLoS One, 2014, 9(2):88617.[48] WALKER A K, BUDAC D P, BISULCO S, et al. NMDA Receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice . Neuropsychopharmacology, 2013, 38(9):1609-1616.[49] LAUTERBACH E C. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan . Med Hypotheses, 2011, 78(6):693-702.[50] MANTOVANI M, PERTILE R, CALIXTO J B, et al. Melatonin exerts an antidepressant-like effect in the tail suspension test in mice:Evidence for involvement of N-methyl-D-aspartate receptors and the L-arginine-nitric oxide pathway . Neurosci Lett, 2003, 343(1):1-4.[51] SUN L, LI Q, LI Q, et al. Chronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys . Addict Biol, 2014, 19(2):185-194.[52] SUN L, LAM W P, WONG Y W, et al. Permanent deficits in brain functions caused by long-term ketamine treatment in mice . Hum Exp Toxicol, 2010, 30(9):1287-1296.